MET and neoplasm: ARGX-111 is a glycoengineered germlined anti-MET mAb that combines four distinct mechanisms of action: (i) blockade of HGF-dependent signaling by ligand displacement; (ii) inhibition of HGF-independent MET signaling by receptor down-regulation; (iii) induction of cytotoxicity against MET-positive tumor cells via enhanced ADCC due to afucosylation in the Fc domain; and (iv) enhanced tumor targeting.